Skip to content
Review

Criteria for Justifying High-Entropy Complexity in Catalytic Cancer Therapy

Sep 2026 · ACS Materials Letters · 0 citations · 54 references

Abstract

High-entropy nanomaterials (HEMs) are advancing catalytic cancer therapy. The prevailing view treats entropy as a performance-enhancing design parameter, assuming it improves activity by broadening active-site chemistries. This review reframes that view as an oversimplification, positioning entropy as a contingent design variable realized only when it resolves durability or robustness limitations beyond lower-entropy materials, not as a general-purpose performance multiplier. Tumor microenvironment constraints—acidity, hypoxia, redox imbalance, and glutathione abundance—limit conventional nanoagents' durability. Under such constraints, entropy-stabilized atomic heterogeneity can generate distributed active sites, electronic delocalization, and resistance to thiol-induced deactivation, enabling functional coexistence beyond compositional additivity. Multifunctionality introduces trade-offs: reduced selectivity, uncontrolled reactive oxygen species generation, and active-site interference. HEMs are justified only when entropy is essential for catalytic persistence under competing biological constraints, not when it merely correlates with improved activity in a single assay. Rigorous benchmarks—phase stability, durability, and lower-entropy comparators—should guide design toward safe, translational deployment.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.